Home / Companies / News / Lupin, Granules India recall 971,000 diabetes drug bottles from US market

Lupin, Granules India recall 971,000 diabetes drug bottles from US market

As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices

Lupin to develop Brazil as Latin American manufacturing, export hub

Premium

Lupin is recalling 1,23,912 bottles of the 500 mg Metformin Hydrochloride extended-release tablets and 3,68,946 bottles of the same drug of 1,000 mg strength.

Press Trust of India New Delhi

2 min read Last Updated : Jul 26 2020 | 3:26 PM IST

Drug makers Lupin and Granules India are recalling close to 971,000 bottles of generic diabetes drug in the US due to possibility of the affected lot containing cancer causing nitrosodimethylamine (NDMA) above the acceptable intake limit.

As per the latest Enforcement Report of the US Food and Drug Administration (USFDA), Lupin is recalling 492,858 bottles of Metformin Hydrochloride extended-release tablets in 500 mg and 1,000 strengths.

On the other hand, Hyderabad-based Granules India is recalling over 478,000 bottles of the drug in 750 mg strength.

As per the USFDA, the companies are recalling the product due to deviation from the

Topics : Lupin Pharma Granules India USFDA Diabetes drug

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in